iData Insights

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 17:07 IST

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 , provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173354/chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173354/chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h2-2015

Table of Contents

Introduction 10

Global Markets Direct Report Coverage 10

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 11

Therapeutics Development 12

Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 12

Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis 13

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 14

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 19

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 25

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 30

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 32

Altor BioScience Corporation 32

Aprea AB 33

arGEN-X BV 34

Ariad Pharmaceuticals, Inc. 35

Array BioPharma Inc. 36

Astex Pharmaceuticals, Inc. 37

Baxalta Incorporated 38

Bellicum Pharmaceuticals, Inc. 39

Bio-Path Holdings, Inc. 40

Biogenomics Limited 41

BioLineRx, Ltd. 42

BioSight Ltd. 43

Boston Biomedical, Inc. 44

Bristol-Myers Squibb Company 45

Cantargia AB 46

Celgene Corporation 47

Constellation Pharmaceuticals, Inc. 48

Daiichi Sankyo Company, Limited 49

Deciphera Pharmaceuticals, LLC 50

Eisai Co., Ltd. 51

EpiZyme, Inc. 52

Galena Biopharma, Inc. 53

Gamida Cell Ltd. 54

HEC Pharm Co., Ltd. 55

Hybrigenics S.A. 56

Ilyang Pharmaceutical Co., Ltd 57

Incyte Corporation 58

Jiangsu Hansoh Pharmaceutical Co., Ltd. 59

Juno Therapeutics Inc. 60

JW Pharmaceutical Corporation 61

KaloBios Pharmaceuticals, Inc. 62

Karyopharm Therapeutics, Inc. 63

Lixte Biotechnology Holdings, Inc. 64

Millennium Pharmaceuticals, Inc. 65

Mirna Therapeutics, Inc. 66

Natco Pharma Limited 67

Novartis AG 68

Onconova Therapeutics, Inc. 69

Ono Pharmaceutical Co., Ltd. 70

Oribase Pharma 71

Pfizer Inc. 72

Pharma Mar, S.A. 73

PharmaEssentia Corporation 74

Selvita SA 75

Shenogen Pharma Group Ltd. 76

Stemline Therapeutics, Inc. 77

Sun Pharma Advanced Research Company Ltd. 78

Targazyme, Inc. 79

Teva Pharmaceutical Industries Limited 80

Threshold Pharmaceuticals, Inc. 81

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 82

Assessment by Monotherapy Products 82

Assessment by Combination Products 83

Assessment by Target 84

Assessment by Mechanism of Action 89

Assessment by Route of Administration 93

Assessment by Molecule Type 95

Drug Profiles 97

(camptothecin + podofilox) - Drug Profile 97

ABL-001 - Drug Profile 98

AIC-47 - Drug Profile 99

ALT-803 - Drug Profile 100

anagrelide hydrochloride CR - Drug Profile 103

APR-246 - Drug Profile 104

ARGX-110 - Drug Profile 106

azacitidine - Drug Profile 109

binimetinib - Drug Profile 113

BL-8040 - Drug Profile 118

BMS-833923 - Drug Profile 120

bosutinib - Drug Profile 122

BP-100101 - Drug Profile 125

BPX-501 - Drug Profile 127

BST-236 - Drug Profile 129

CAN-04 - Drug Profile 130

Cell Therapy to Target GM-CSF for Oncology - Drug Profile 132

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 134

CPI-0610 - Drug Profile 135

CT-413 - Drug Profile 136

CWP-291 - Drug Profile 137

D-12PGJ3 - Drug Profile 139

D-824 - Drug Profile 140

danusertib - Drug Profile 141

Dendritic Cell Therapy for Chronic Myeloid Leukemia - Drug Profile 143

Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 144

Dendritic Cell Therapy for Oncology - Drug Profile 145

Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 146

Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 147

DS-3032 - Drug Profile 148

E-6201 - Drug Profile 149

erismodegib - Drug Profile 151

ETC-027 - Drug Profile 154

ETC-219 - Drug Profile 155

evofosfamide - Drug Profile 156

flumatinib mesylate - Drug Profile 164

Gene Therapy for Oncology - Drug Profile 165

guadecitabine - Drug Profile 166

Hu8F4 - Drug Profile 170

inecalcitol - Drug Profile 171

inotuzumab ozogamicin - Drug Profile 174

interferon alfa-2a - Drug Profile 176

interferon alfa-2b - Drug Profile 177

ipilimumab - Drug Profile 178

ixazomib citrate - Drug Profile 183

JTCR-016 - Drug Profile 187

KB-004 - Drug Profile 188

LB-100 - Drug Profile 190

LB-102 - Drug Profile 192

lirilumab - Drug Profile 194

lurbinectedin - Drug Profile 196

MJ-05 - Drug Profile 199

MRX-102 - Drug Profile 200

MRX-34 - Drug Profile 202

napabucasin - Drug Profile 204

NiCord - Drug Profile 207

nivolumab - Drug Profile 208

NOV-120501 - Drug Profile 216

NRCAN-019 - Drug Profile 217

omacetaxine mepesuccinate - Drug Profile 219

ORB-0001 - Drug Profile 222

pegaspargase - Drug Profile 223

PF-114 - Drug Profile 225

pinometostat - Drug Profile 226

ponatinib hydrochloride - Drug Profile 229

PRI-724 - Drug Profile 232

radotinib - Drug Profile 234

rebastinib tosylate - Drug Profile 236

rigosertib sodium - Drug Profile 238

ropeginterferon alfa-2b - Drug Profile 243

ruxolitinib phosphate - Drug Profile 246

SEL-24B489 - Drug Profile 251

selinexor - Drug Profile 252

SL-401 - Drug Profile 258

SL-501 - Drug Profile 260

Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia - Drug Profile 261

Small Molecules to Inhibit Abl Tyrosine Kinase for CML - Drug Profile 262

Small Molecules to Inhibit BCR-ABL for CML - Drug Profile 263

Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile 264

Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer - Drug Profile 265

SNG-1153 - Drug Profile 266

SNG-162 - Drug Profile 267

SUNK-706 - Drug Profile 269

TR-120 - Drug Profile 270

trametinib dimethyl sulfoxide - Drug Profile 271

TZ-101 - Drug Profile 274

Vaccine to Target Bcr-Abl Tyrosine Kinase for Chronic Myeloid Leukemia - Drug Profile 276

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 277

Vaccine to Target WT1 for CML and AML - Drug Profile 278

Vaccine to Target WT1 for Oncology - Drug Profile 279

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 280

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 414

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 420

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 422

Featured News & Press Releases 422

Appendix 433

Methodology 433

Coverage 433

Secondary Research 433

Primary Research 433

Expert Panel Validation 433

Contact Us 433

Disclaimer 434"

Read More http://www.idatainsights.com/reports-landing-page.php?id=173354/chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects